Investigational BACE inhibitors for the treatment of Alzheimer’s disease
The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Introduction : The amyloid hypothesis of Alzheimer's disease (AD) states that brain accumulation of amyloid-β (Aβ) oligomers and soluble aggregates represents the major causal event of the disease. Several small organic molecules have been synthesized and developed to inhibit the enzyme (β-site amyloid precursor protein cleaving enzyme-1 or BACE1) whose action represents the rate-limiting step in Aβ production. Areas covered : We reviewed the pharmacology and clinical trials of major BACE1 inhibitors. Expert opinion : In transgenic mouse models of AD, BACE1 inhibitors dose-dependently lower Aβ levels in brain and cerebrospinal fluid (CSF) but the evidence for attenuation or reversal cognitive or behavioral deficits is very scanty. In AD patients, BACE1 inhibitors robustly lower plasma and CSF Aβ levels and reduce brain plaques but without cognitive, clinical, or functional benefit. To date, seventeen BACE1 inhibitors have failed in double-blind, placebo-controlled clinical trials in patients with mild-to-moderate or prodromal AD, or in cognitively normal subjects at risk of developing AD. Several of these studies were prematurely interrupted due to toxicity or cognitive and behavioral worsening compared to placebo-treated patients. Elenbecestat, the last BACE1 inhibitor remaining in late clinical testing for AD, was recently discontinued due to safety concerns.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elenbecestat (15, E2609), a fourth-generation BACE1 inhibitors, was among the last BACE1 inhibitors to reach phase III clinical trials.448”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [448]
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease
Kivipelto, M., Mangialasche, F., & Ngandu, T. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0070-3 · Cited by 1,173
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Self-citationElevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Research works printed but not linked: 6
- Vassar R, 2019, J Prev Alzheimers Dis, 6, 78
- Strobel G, 2019, Alzheimer Res Forum, 17
- Lo AC, 2018, J Prev Alzheimers Dis, 5, S37
- Shugart J, 2019, Alzheimer Res Forum, 12
- Caouette D Eisai and Biogen to discontinue phase III clinical studies of BACE inhibitor elenbecestat in early Alzheimer’s disease. Eisai’s press release;2019 Sept 13.
- Schneeberger A, 2015, J Prev Alzheimers Dis, 2, 103
Cited by
Items 101–135 of 135
Advances in Alzheimer's Disease Biomarkers
Li, K., Gao, Y., Liu, M., & Chen, Y. (2024) · Current Alzheimer Research · doi:10.2174/0115672050366767241223050957 · Cited by 3
Chen, S., Zhou, J., Wang, S., Chen, E., Zhuang, K., Lin, R., Liang, C., Can, D., Li, H., Li, J., et al. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003259 · Cited by 2
“Importantly, early intervention with BACE1 inhibitors could potentially delay AD progression by reducing early A β accumulation [7,51,52].”
Wagdy, M., Ibrahim, A. A., Yahia, A. M., Maher, R. M., Abo-Elwafa, A. H., Salah, A., & Heikal, Y. M. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578821 · Cited by 2
Perpectivas atuais da terapia antiamiloide para a Doença de Alzheimer
Cardoso, A. M. S., Bezerra, L. M. R., Lima, C. C., Bezerra, I. M. R., Júnior, J. L. P., & Torres, J. G. P. (2022) · Revista Neurociências · doi:10.34024/rnc.2022.v30.13552 · Cited by 3
Commentary: Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review
Bhagavati, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.895398 · Cited by 2
“For example treatment with β-site-APP cleaving enzyme 1 (BACE1) inhibitors (Imbimbo and Watling, 2019) or infusions of aducanumab, a monoclonal antibody that selectively targets aggregated Aβ drastically reduces amyloid load (Sevigny et al.”
BackgroundPeyvand, P., Allami, P., & Rezaei, N. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0025 · Cited by 1
Sakarya, M. T., Yamalı, C., Ertürk, A., Sert, Y., Gul, H. I., Gül, M., & Gulcin, I. (2026) · Chemical Papers · doi:10.1007/s11696-026-04771-z · Cited by 1
“Umibece - stat (CNP520) and Elenbecestat (E2609) were reported a fourth-generation BACE1 inhibitors under clinical studies (Imbimbo and Watling 2019).”
Malenchini, M., Beretti, F., Gatti, M., Bertucci, E., Toro, E. D., & Maraldi, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114834 · Cited by 1
“…neurons, such as amyloid-β oligomers, was induced by LPS-treatment: we investigated the modulation of intracellular AD markers using the antibody 6E10, which is specific for human amyloid precursor protein (APP), A β oligomers [13], and molecules generated from cleavage of APP by secretases [14].”
Structural Scaffolds as Anti- Alzheimer Agents
Alka, T., Sati, B., & Chaudhary, A. (2022) · Medicinal Chemistry · doi:10.2174/1573406418666220815101124 · Cited by 2
Nanocrystals: a new herald for the management of Alzheimer’s disease
Patel, V. F., Rajput, M. S., Patel, A. K., Patel, M., & Patel, R. J. (2024) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2024.2409443 · Cited by 1
“[30,31] Eventually with the production of A b , a cascade of events gets initiated leading to formation of amyloid oligomers which later become the leading cause of neuro-toxicity (inflammation, oxidation, excessive glutamate production, alteration in ionic homeostasis and tau…”
Early Development of Erenumab for Migraine Prophylaxis
Vargas, G. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-62351-7_17 · Cited by 1
Khan, A., Killick, R., Wirth, D., Hoogland, D., Hristova, K. A., Ulmschneider, J. P., King, C. R., & Ulmschneider, M. B. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12428
Lucero, E., Freund, R. K., Johnson, N. R., Dooling, B. R., Sullivan, E. M., Prikhodko, O., Ahmed, M. M., Dell’Acqua, M. L., Chial, H. J., & Potter, H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.09.459627
“Many current experimental treatments for AD have focused on reducing Aβ production or on increasing the clearance of Aβ plaques (reviewed in (Imbimbo and Watling, 2019, Demattos et al., 2012)).”
BackgroundSmirnova, A. A., Прахова, Л. Н., & Ilves, A. G. (2021) · Russian neurological Journal · doi:10.30629/2658-7947-2021-26-5-4-15 · Cited by 1
Young, R. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc242.pub2
Alzheimer’s disease as a syndrome of overloaded amyloidic synaptic tagging in memory networksPreprint
Murphy, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7gsaz
Advantages and limitations of hiPSC-derived neurons for the study of neurodegeneration
Mishra, S., Deursen, C. V., Robert, A., van der Kant, R., & Young, J. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822277-5.00016-x
Huang, L., Zhong, X., Xu, Y., Deng, M., & Zhou, Z. (2023) · Pharmacognosy Magazine · doi:10.1177/09731296231168743 · Cited by 2
Sasmita, A. O. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10403 · Cited by 1
A Comprehensive Review on the Newer Therapeutic Approaches in Treating Alzheimer’s Disease
Prakash, R., Jayaraman, R., Palei, N. N., Prakash, D. J., & Ronald, D. (2024) · Springer eBooks · doi:10.1007/978-981-19-3949-5_40-1 · Cited by 1
A Comprehensive Review on the Newer Therapeutic Approaches in Treating Alzheimer’s Disease
Prakash, R., Jayaraman, R., Palei, N. N., Prakash, D. J., & Ronald, D. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_40
Early Development of Erenumab for Migraine Prophylaxis
Vargas, G. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-61992-2_25
Modeling amyloid plaque turnover dynamics improves characterization of drug effects
van Maanen, E., Robey, S., Bennacef, I., Duffull, S. B., Egan, M. F., Kennedy, M. E., & Stone, J. A. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70169
Bell, N. A., Imami, A. S., Srivatsan, M., Jiang, N., Musalgavkar, A., Ridi, A., & McCullumsmith, R. E. (2025) · Translation The University of Toledo Journal of Medical Sciences · doi:10.46570/utjms-2025-1901
Exploring boswellic acids as a multitarget therapeutic treatment for Alzheimer’s disease
Patil, D. N., & Barvkar, V. T. (2026) · Journal of Biologically Active Products from Nature · doi:10.1080/22311866.2025.2610615 · Cited by 1
Ugwah-Oguejiofor, C. J., Okechukwu, P. N., Mathias, S. N., Ofokansi, M. N., & Janakiraman, A. K. (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-49144-3.00007-1
Ragolia, L. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00552-y
“In AD, BACE1 inhibitors reduce Aβ production but were largely unsuccessful in phase III trials due to mechanism-based side effects and, likely, intervention too late in the disease course [201, 202].”
Jose, J., Varughese, J. K., & Mathew, T. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100566
Ahmad, W., Zhu, X., Khan, S. S., Bai, Y., & Pei, P. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-11068-x
“…demonstrated effective Aβ40 and Aβ42 level reduction in vivo [ 15], many candidate inhibitors were discontinued during phase 1 or the early phase 2 due to organ specific toxicity; liver toxicity in case of LY2886721, ocular toxicity with LY2811376 and cardiac adverse effects from AZD-3839 [ 9].”
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“The fourth-generation BACE1 inhibitor Elenbecestat (E2609) also underwent phase III studies before being withdrawn, regretta-bly (180).”
Metadata
- Authors
- Imbimbo, B. P., & Watling, M.
- Affiliations
- Chiesi (Italy) (IT)
- CNS & Pain Department, TranScrip Partners, Reading, UK
- Corresponding author
- Imbimbo, Bruno P.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2019-10-29
- Volume
- 28
- Issue
- 11
- Pages
- 967-975
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2982501787
- Cited by
- 132
- References
- 61
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 21 · 2023: 22 · 2022: 20 · 2021: 38 · 2020: 14
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- BACE1 inhibitors, Alzheimer's disease, amyloid hypothesis, amyloid-beta, amyloid plaques, cerebrospinal fluid amyloid-beta, clinical trial failure, drug safety, cognitive decline, transgenic mouse model
- MeSH terms
- Drug Development, Alzheimer Disease, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Mice, Transgenic, Drugs, Investigational, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.